Regeneron’s Phase II study indicates investigational trevogrumab reduces lean-mass and thigh-muscle loss in adults taking semaglutide for weight management.
At the recent European Association for the Study of Diabetes Annual Meeting, Regeneron presented Phase II data showing that an investigational drug called trevogrumab reduced lean-mass loss in adults taking semaglutide. The company also noted the findings are in press with The Lancet.
The COURAGE study evaluated the effects of an investigational myostatin-blocking antibody on adults living with obesity. The trial tested semaglutide 2.4 mg with or without lower doses of trevogrumab for 52 weeks. Researchers sought to measure changes in lean tissue during medically supervised weight loss.
The trial also tracked body composition changes at the midway point of the year. At week 26, lean-mass loss reached 6.7 percent for participants taking semaglutide alone. The groups taking the myostatin blocker showed less severe tissue reductions. The 25 mg and 75 mg doses restricted lean-mass loss to 4.7 percent and 3.3 percent.
Regeneron reported relative tissue preservation of 29.9 percent and 50.7 percent for those respective lower doses at week 26. These figures represent the proportion of tissue reduction avoided compared to the control group. They do not indicate that participants gained that percentage of lean mass during the trial. The data illustrates a consistent trend of tissue retention extending from the six-month mark to the end of the year.
The trial included a specific MRI substudy to assess changes in thigh muscle volume. This supporting measure provides a different perspective than whole-body lean mass scans. At week 52, thigh-muscle-volume loss was 1.03 units with semaglutide alone. The 25 mg and 75 mg combination doses reduced this loss to 0.29 and 0.32 units.
The company reported these unit changes as relative muscle preservation of 71.8 percent and 68.9 percent. The 26-week MRI results showed similar preservation rates of 63.6 percent and 72.7 percent. Lead investigator Julio Rosenstock stated that these MRI measurements of muscle volume further validated the one-year clinical findings.
Researchers conducted a predefined subgroup analysis focused on patients with less initial muscle. They defined low lean mass using an imaging component of a recognized sarcopenia definition. Participants matching this criteria lost more lean mass when taking semaglutide alone compared to the broader study population.
These vulnerable participants showed numerically greater tissue preservation when trevogrumab was added to their treatment plan. The data indicates that individuals starting with less physical reserve face higher risks of tissue depletion during significant weight loss. This subgroup finding highlights the clinical importance of monitoring body composition in patients with existing physical deficits.
Trevogrumab is currently an unapproved medication in the clinical testing phase. Regeneron states that its safety and efficacy have not been evaluated by a regulatory authority. In the lower-dose study portion, at least one adverse event was reported in 77 percent of participants receiving the antibody. This compared to an 82 percent adverse event rate in the placebo group.
The company described the lower doses as generally well tolerated by participants. Regeneron listed nausea, constipation, diarrhea, and vomiting among the most common adverse events. Each of these specific issues occurred in at least 10 percent of the trial patients.
MedicalXpress reported separate safety data concerning a higher-dose portion of the trial. That specific trial arm tested a three-drug combination including semaglutide, trevogrumab, and garetosmab. The three-drug arm showed higher serious adverse-event rates and discontinuation rates than the other groups. These specific combination results should not be conflated with the safety profile of the lower-dose trevogrumab groups.
For an aging man managing his physical health, these trial results emphasize the value of tracking internal body composition. GLP-1 receptor agonists provide powerful tools for fat reduction, but they also introduce risks to existing physical reserves. Regeneron executive Boaz Hirshberg stated that muscle loss with these medicines is a particular concern for older adults or those facing frailty.
Understanding the difference between lean mass and skeletal muscle is crucial for setting realistic aesthetic and functional goals. The COURAGE study assessed lean mass with DXA scans and thigh muscle volume with MRI scans. These two clinical measurements are not interchangeable. Lean mass includes water weight and organ tissue, while the MRI substudy specifically measured actual skeletal muscle volume.
The MRI findings come from a focused substudy rather than the full trial population. They serve as a supporting measure for the primary DXA results. When an aging man evaluates his own body composition targets, he should recognize that preserving clinical lean mass does not automatically equal maintaining visible muscularity. Both metrics require dedicated attention during any intentional weight-loss phase.
The study authors noted that important clinical questions remain unanswered. Further research is necessary to determine whether preserving muscle during weight loss actually improves long-term physical function. It is also unclear if this tissue retention translates into measurable improvements in metabolic health or other clinical outcomes. Adding muscle volume without improving actual strength may not fully resolve the functional risks of rapid weight reduction.
Men starting a health program with lower muscle density should be especially proactive about their physical baseline. The subgroup data showing greater tissue loss in patients with low baseline lean mass offers a clear warning. Aging men who lack significant physical reserves should discuss targeted preservation strategies with their medical providers before beginning intense fat-loss protocols.
These trial results do not establish that trevogrumab is an approved or appropriate addition to a standard clinical routine. The findings specifically concern adults with obesity receiving semaglutide under strict trial conditions. They do not prove that myostatin blockers preserve muscle during dietary restriction or other weight-loss approaches. The results also do not apply to men without obesity who simply want to alter their physical appearance.
For a gay man navigating physical changes after 35, the balance between looking attractive and feeling energetic becomes increasingly complex. Slower recovery times and subtle changes in physical capability often complicate standard fitness advice. When men attempt to optimize their appearance through rapid weight reduction, they frequently encounter conflicting guidance about how to protect their existing physical foundation. The early data from the COURAGE trial provides a clear physiological reminder that aggressive fat reduction places systemic stress on the body.
While pharmaceutical interventions like GLP-1 medications effectively reduce body mass, the resulting changes in energy and metabolic function require careful management. Men seeking a leaner physique often prioritize scale weight over actual cellular health. The clinical focus on retaining thigh-muscle volume highlights a critical truth about healthy aging. Maintaining functional leg strength directly impacts a man's long-term mobility, joint stability, and overall physical independence.
These trial measurements validate the need for a comprehensive approach to body composition. Focusing exclusively on visible abdominal fat while ignoring the density of major muscle groups can lead to an undesirable physical state. An aging man who loses significant lean tissue may appear smaller, but he often experiences decreased stamina and diminished physical confidence. By recognizing the clinical risks of tissue depletion, men can adjust their training routines to prioritize sustainable strength alongside aesthetic improvements.
The medical landscape surrounding weight management is shifting rapidly. This constant influx of clinical data creates confusion around healthy aging claims and aesthetic promises. When researchers test investigational antibodies like trevogrumab, the media often translates early trial results into premature lifestyle advice. Men must maintain a healthy skepticism toward any new chemical intervention that has not secured official regulatory approval.
Integrating these clinical developments into a comprehensive longevity plan requires clear communication with a medical professional. A man who wants to protect his physical vitality should evaluate his sleep quality, energy levels, and nutritional habits before seeking novel pharmaceutical combinations. The most effective strategy for managing nutrition and metabolism remains grounded in consistent lifestyle habits.
The COURAGE study results support continued clinical development rather than immediate behavioral changes. Rosenstock noted that the findings encourage further research into muscle preservation within obesity care. As researchers plan new trials for older adults with decreased physical strength, the medical community will gradually develop better frameworks for metabolic treatment. Until those established guidelines arrive, a man should focus on optimizing his natural physical capabilities through intelligent training and careful medical consultation.
The trial data points toward future applications in specifically vulnerable patient groups. Regeneron says its planned Phase II trial will target older adults living with obesity who already have decreased muscle mass or physical strength. This strategic focus acknowledges that losing lean tissue carries distinct risks for an aging body. An older man cannot replace lost skeletal muscle as easily as a younger patient facing the same body composition changes.
When older adults experience severe lean-mass reduction, the corresponding drop in physical function can alter their daily independence. The planned clinical trials reflect a growing medical recognition that preserving tissue quality matters just as much as reducing total body fat. Until these specialized treatments finish testing, aging men face a practical mandate to defend their existing muscle density. Engaging in regular physical conditioning provides a proven defense against the tissue loss associated with standard weight-loss therapies.
An aging man focused on longevity must coordinate his fitness and medical inputs carefully. A cautious approach involves discussing specific strength goals and functional concerns with a qualified physician. This active communication helps distinguish established medical care from early-stage research drugs.
Regeneron plans to conduct a subsequent Phase II trial of trevogrumab paired with GLP-1 therapies. The company says this future study will focus specifically on older adults with obesity and decreased muscle mass or strength. Until new therapeutic options complete rigorous testing, men must rely on established resistance training and protein protocols to support their physical health.
Integrating these clinical insights into a daily routine requires an objective assessment of physical priorities. If a man chooses a medically supervised fat-loss path, he should actively monitor his strength levels and physical fatigue. Tracking actual physical performance provides a practical way to gauge functional health while researchers continue to study pharmaceutical tissue preservation.
A man prioritizing his long-term physical independence should proactively discuss muscle preservation strategies with his physician before beginning any rapid fat-loss protocol.
Preserving functional muscle mass during medically supervised weight loss requires a man to coordinate clinical treatments with sustainable fitness strategies. Conflicting advice about fitness, body composition and metabolism after 35 often complicates this process, a challenge GayFitLab solves by translating credible evidence into practical guidance without medical hype. Explore Resources
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
